By Counterforce Health Team in Keytruda (pembrolizumab) —

How to Get Keytruda (pembrolizumab) Covered by Blue Cross Blue Shield in New Jersey: Forms, Appeals, and Provider Collaboration Guide

Answer Box: Getting Keytruda Covered in New Jersey

Blue Cross Blue Shield requires prior authorization for Keytruda (pembrolizumab) in New Jersey. The fastest path: Submit a complete PA request with diagnosis, PD-L1 testing results (when required), and prior treatment documentation. If denied, you have 60 days to file an external appeal through New Jersey's IHCAP program via Maximus Federal Services. First step today: Contact your oncology team to gather your medical records and confirm your Blue Cross Blue Shield plan's specific requirements through their provider portal.

Table of Contents

  1. Set Your Goal: Understanding Blue Cross Blue Shield Requirements
  2. Visit Preparation: What to Document
  3. Building Your Evidence Kit
  4. Letter of Medical Necessity Structure
  5. Supporting Your Provider During Peer-to-Peer Reviews
  6. After Your Visit: Documentation and Follow-up
  7. Appeals Process: New Jersey IHCAP
  8. Common Denial Reasons and Solutions
  9. Costs and Financial Assistance
  10. FAQ

Set Your Goal: Understanding Blue Cross Blue Shield Requirements

Keytruda (pembrolizumab) requires prior authorization from all Blue Cross Blue Shield plans in New Jersey, including Horizon Blue Cross Blue Shield. Your approval depends on meeting specific medical criteria that vary by cancer type and treatment line.

Coverage at a Glance

Requirement What It Means Where to Find It
Prior Authorization Required before treatment starts Horizon BCBSNJ Provider Portal
PD-L1 Testing CPS score required for certain cancers FDA-approved assay results
Formulary Status Specialty tier medication Plan formulary document
Step Therapy May require trying other treatments first Medical policy guidelines
Site of Care Typically covered in oncology infusion centers Provider network directory

Key Partnership Strategy: Your oncologist handles the clinical justification, but you can streamline the process by organizing your medical history and staying responsive to requests for additional information.

Note: New Jersey enacted updated prior authorization laws effective 2025 that may impact processing timelines. Verify current requirements with your plan.

Visit Preparation: What to Document

Come to your oncology appointment prepared with a comprehensive timeline of your cancer journey. This preparation helps your provider build the strongest possible case for Keytruda coverage.

Essential Information to Gather

Symptom and Diagnosis Timeline:

  • When symptoms first appeared
  • Dates of initial diagnosis and staging
  • Pathology report details
  • Biomarker testing results (PD-L1, MSI, TMB)

Treatment History:

  • All previous therapies tried (chemotherapy, radiation, surgery)
  • Dates of treatment start and stop
  • Reasons for discontinuation (progression, toxicity, intolerance)
  • Response to each treatment (stable, partial response, progression)

Current Functional Status:

  • How cancer affects daily activities
  • Performance status changes
  • Quality of life impacts
  • Treatment goals and preferences
Tip: Create a simple timeline document or use your phone's notes app to track this information between appointments.

Building Your Evidence Kit

Your evidence kit supports your provider's medical necessity argument. Gather these documents before your appointment:

Required Medical Records

Laboratory and Imaging:

  • Recent staging scans (CT, PET, MRI)
  • Blood work including tumor markers
  • PD-L1 testing results with CPS score
  • Pathology reports confirming diagnosis

Treatment Documentation:

  • Discharge summaries from previous treatments
  • Chemotherapy administration records
  • Radiation therapy summaries
  • Surgical reports and post-operative notes

Insurance Documentation:

  • Current insurance card and member ID
  • Previous denial letters (if applicable)
  • Explanation of Benefits (EOB) statements
  • Plan formulary or drug list

Published Guidelines Support

Your provider will reference these evidence sources:

Letter of Medical Necessity Structure

Your oncologist will write a letter of medical necessity that follows this proven structure:

Essential Components

Patient and Diagnosis Information:

  • Full name, date of birth, insurance ID
  • Complete cancer diagnosis with staging
  • ICD-10 codes for primary and secondary diagnoses
  • Relevant biomarker results (PD-L1 CPS when required)

Clinical Rationale:

  • Why Keytruda is appropriate for your specific situation
  • How it aligns with FDA-approved indications
  • Treatment goals and expected outcomes
  • Monitoring plan and safety considerations

Prior Treatment Documentation:

  • Detailed history of previous therapies
  • Clinical response or reasons for discontinuation
  • Why alternative treatments are not suitable
  • Evidence of step therapy completion (if required)

Supporting Evidence:

  • References to FDA labeling and clinical guidelines
  • Peer-reviewed literature supporting use
  • Professional society recommendations
  • Relevant clinical trial data
From our advocates: We've seen the strongest letters include specific details about why formulary alternatives won't work—such as documented allergies, previous treatment failures, or contraindications based on the patient's medical history. These concrete clinical facts make the medical necessity argument much more compelling.

Supporting Your Provider During Peer-to-Peer Reviews

When Blue Cross Blue Shield requests a peer-to-peer review, you can help your provider prepare for this critical conversation.

How to Assist Your Provider

Availability Coordination:

  • Provide flexible time windows when you're available for questions
  • Ensure your provider has updated contact information
  • Be responsive to calls or messages during the review period

Case Summary Preparation: Help your provider prepare by organizing:

  • Concise timeline of your cancer progression
  • List of treatments tried and outcomes
  • Current symptoms and functional limitations
  • Treatment urgency factors

Documentation Support:

  • Ensure all relevant records are in your provider's system
  • Provide any missing test results or outside records
  • Confirm insurance information is current and accurate

What Happens During the Review

Your provider will speak directly with a Blue Cross Blue Shield medical reviewer to discuss:

  • Your specific clinical situation
  • Medical necessity for Keytruda
  • Why alternative treatments aren't appropriate
  • Evidence supporting the treatment decision

You typically won't participate in this call, but being available for clarifying questions helps your provider respond comprehensively.

After Your Visit: Documentation and Follow-up

Proper documentation after your appointment ensures nothing falls through the cracks during the approval process.

What to Save and Track

Clinical Documentation:

  • Visit summary with treatment plan
  • Updated medication list
  • Laboratory and test orders
  • Follow-up appointment schedules

Insurance Communications:

  • Prior authorization submission confirmations
  • Reference numbers for all requests
  • Timeline for expected decisions
  • Contact information for follow-up

Provider Portal Access:

  • Learn how to access your patient portal
  • Understand how to message your care team
  • Know how to view test results and updates
  • Set up notifications for new messages

Communication Strategies

With Your Provider:

  • Use secure messaging through the patient portal
  • Call during designated phone hours for urgent questions
  • Provide updates on any symptom changes
  • Report insurance communication promptly

With Blue Cross Blue Shield:

  • Keep detailed records of all phone calls
  • Save confirmation numbers for submissions
  • Document names and dates of conversations
  • Follow up in writing when possible

Appeals Process: New Jersey IHCAP

If Blue Cross Blue Shield denies coverage for Keytruda, New Jersey's Independent Health Care Appeals Program (IHCAP) provides an external review process administered by Maximus Federal Services.

Step-by-Step Appeals Process

1. Complete Internal Appeals First

  • File with Blue Cross Blue Shield within plan-specified timeframe
  • Provide additional medical documentation
  • Wait for final internal denial decision
  • Save all correspondence and decision letters

2. File External Appeal with IHCAP

  • Submit within 60 calendar days of final internal denial
  • Use Maximus IHCAP portal or call 1-888-866-6205
  • Include all medical records and denial letters
  • Specify if requesting expedited review (48 hours vs. 45 days)

3. Independent Medical Review

  • Maximus assigns case to independent physician reviewer
  • Reviewer evaluates medical necessity based on clinical evidence
  • No cost to you—insurers pay all review fees
  • Decision is binding on Blue Cross Blue Shield

Required Documentation for Appeals

Document Type Purpose Where to Obtain
Denial Letters Shows internal appeal completion Blue Cross Blue Shield
Medical Records Supports medical necessity Your oncology team
Provider Letter Clinical rationale for treatment Your oncologist
Treatment History Documents prior therapy failures Medical records
Guidelines/Literature Evidence-based support Provider or medical library
Important: New Jersey law requires insurers to comply with favorable IHCAP decisions. If the independent reviewer overturns the denial, Blue Cross Blue Shield must cover your Keytruda treatment.

Common Denial Reasons and Solutions

Understanding why Blue Cross Blue Shield denies Keytruda requests helps you and your provider address these issues proactively.

Typical Denial Reasons and Fixes

Denial Reason Solution Required Documentation
Missing PD-L1 testing Obtain FDA-approved assay Laboratory report with CPS score
Wrong line of therapy Document prior treatment failures Treatment records and response data
Off-label use Provide evidence-based justification Clinical guidelines and literature
Incomplete staging Submit complete pathology Staging scans and pathology reports
Step therapy not met Document contraindications or failures Medical records showing why alternatives won't work
Quantity limits exceeded Justify dosing based on weight/BSA Clinical rationale for specific dosing

Strengthening Your Case

Clinical Documentation:

  • Ensure all biomarker testing is complete and reported
  • Document progression on previous therapies
  • Include performance status and quality of life measures
  • Provide clear treatment goals and monitoring plans

Evidence-Based Support:

  • Reference current NCCN guidelines for your cancer type
  • Include relevant clinical trial data
  • Cite FDA labeling for approved indications
  • Provide peer-reviewed literature when appropriate

Costs and Financial Assistance

Keytruda's cost—approximately $23,591 per six-week dose according to Merck—makes financial assistance crucial for most patients.

Manufacturer Support Programs

Merck Access Program:

  • Copay assistance for commercially insured patients
  • May reduce out-of-pocket costs to $25 per treatment
  • Income and insurance restrictions apply
  • Apply through Merck website or ask your oncology team

Additional Financial Resources

Foundation Grants:

  • Patient Access Network Foundation
  • HealthWell Foundation
  • Cancer Financial Assistance Coalition
  • Local cancer center financial counseling

State Programs:

  • New Jersey cancer assistance programs
  • Medicaid coverage through NJ FamilyCare
  • State pharmaceutical assistance programs
Tip: Many oncology practices have financial counselors who specialize in insurance navigation and assistance program applications. Ask to speak with one early in your treatment planning.

FAQ

How long does Blue Cross Blue Shield prior authorization take in New Jersey? Routine requests are typically processed within 5-7 business days, while urgent requests may be completed within 24-48 hours. Verify current timelines with your specific plan.

What if Keytruda is non-formulary on my Blue Cross Blue Shield plan? You can request a formulary exception by demonstrating medical necessity and showing that formulary alternatives are inappropriate. Your provider must document why covered drugs won't work for your specific situation.

Can I request an expedited appeal in New Jersey? Yes, if a delay would cause serious harm to your health, you can request expedited review through IHCAP. Expedited appeals are decided within 48 hours rather than the standard 45 days.

Does step therapy apply if I received previous treatment outside New Jersey? Treatment records from any location should count toward step therapy requirements. Ensure your provider submits complete documentation of all prior therapies, regardless of where you received them.

What happens if my Blue Cross Blue Shield plan changes during treatment? Contact your new plan immediately to initiate prior authorization. Ongoing treatment may qualify for continuity of care provisions, but you'll need to verify coverage terms with the new plan.

Can my provider file an external appeal on my behalf? Yes, New Jersey allows providers to file IHCAP appeals with patient consent. This can be helpful since providers understand the clinical and administrative requirements better than most patients.

How often do external appeals succeed for cancer drugs like Keytruda? While specific success rates for Keytruda aren't published, external appeals for oncology drugs often have substantial overturn rates when supported by strong clinical evidence and proper documentation.

What if I need Keytruda for an off-label indication? Off-label use requires stronger evidence-based justification. Your provider will need to reference clinical guidelines, peer-reviewed literature, and demonstrate why FDA-approved alternatives aren't appropriate for your situation.

At Counterforce Health, we help patients, clinicians, and specialty pharmacies turn insurance denials into successful appeals by creating targeted, evidence-backed responses. Our platform analyzes denial letters and plan policies to draft point-by-point rebuttals that address payers' specific concerns while incorporating the right clinical evidence and procedural requirements.

Working with your oncology team and understanding Blue Cross Blue Shield's requirements gives you the best chance of getting Keytruda covered in New Jersey. The state's robust external appeal process through IHCAP provides an important safety net when internal appeals don't succeed. Remember that Counterforce Health can help streamline this process by identifying denial reasons and crafting appeals that meet payer-specific workflows and documentation requirements.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical advice. Treatment decisions should always be made in consultation with qualified healthcare providers. Insurance coverage varies by plan and individual circumstances. Always verify current requirements with your specific Blue Cross Blue Shield plan and consult with your oncology team about the most appropriate treatment options for your situation.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.